Lv1
40 积分 2023-05-31 加入
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
17天前
已完结
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial
19天前
已完结
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
19天前
已完结
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
2个月前
已完结
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
3个月前
已完结
Comparison of tucidinostat with CHOP-like versus CHOP-like in first-line treatment of peripheral T-cell lymphoma: a single-center real-world study
5个月前
已完结
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
5个月前
已完结
Cancer Statistics
6个月前
已完结
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
7个月前
已完结
Comprehensive blood group antigen profile predictions for Western Desert Indigenous Australians from whole exome sequence data
8个月前
已完结
皖公网安备34019202002308
